Canadian biopharmaceutical company QLT has announced that Michael Doty is to step down as CFO with immediate effect, though there was no indication that this was linked to poor performance. CEO Paul Hastings said Doty had implemented a new standard of financial discipline at the company. "He introduced a new budgeting process that has allowed us to better control and manage our business, he put in a highly effective foreign currency exposure risk management strategy, and he has worked diligently to meet the many new requirements of corporate governance, including those of the Sarbanes-Oxley Act," he said.
April 12, 2005